id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-N-2527-8031,FDA,FDA-2016-N-2527,Exhibit E-3 - Appendix B to Citizen Petition re Comment from RAI Services Company,Supporting & Related Material,Background Material,2017-08-09T04:00:00Z,2017,8,,,2017-08-09T15:02:42Z,,0,0,09000064828d2eb3
FDA-2016-N-2527-8037,FDA,FDA-2016-N-2527,Exhibit G-4 - Attachment 3 to Second Supplement to Citizen Petition re Comment from RAI Services Company,Supporting & Related Material,Background Material,2017-08-09T04:00:00Z,2017,8,,,2017-09-07T17:45:09Z,,0,0,09000064828d1da9
FDA-2016-N-2527-8030,FDA,FDA-2016-N-2527,Exhibit E-2 - Appendix A to Citizen Petion re Comment from RAI Services Company,Supporting & Related Material,Background Material,2017-08-09T04:00:00Z,2017,8,,,2017-08-09T14:23:15Z,,0,0,09000064828d2eb2
FDA-2016-N-2527-8027,FDA,FDA-2016-N-2527,Exhibit C - re Comment from RAI Services Company,Supporting & Related Material,Background Material,2017-08-09T04:00:00Z,2017,8,,,2017-08-09T13:48:47Z,,0,0,09000064828d2eaf
FDA-2016-N-2527-8029,FDA,FDA-2016-N-2527,"Exhibit E-1 - Citizen Petition dated July 28, 2011 re Comment from RAI Services Company",Supporting & Related Material,Background Material,2017-08-09T04:00:00Z,2017,8,,,2017-08-09T14:11:01Z,,0,0,09000064828d2eb1
FDA-2016-N-2527-8026,FDA,FDA-2016-N-2527,Exhibit B - re Comment from RAI Services Company,Supporting & Related Material,Background Material,2017-08-09T04:00:00Z,2017,8,,,2017-08-09T13:48:54Z,,0,0,09000064828d2eae
FDA-2016-N-2527-8033,FDA,FDA-2016-N-2527,Exhibit F-2 - Appendix A to First Supplement to Citizen Petition re Comment from RAI Services Company,Supporting & Related Material,Background Material,2017-08-09T04:00:00Z,2017,8,,,2017-08-09T15:01:24Z,,0,0,09000064828d1da5
FDA-2016-N-2527-8034,FDA,FDA-2016-N-2527,Exhibit G-1 - Second Supplement to Citizen Petition re Comment from RAI Services Company,Supporting & Related Material,Background Material,2017-08-09T04:00:00Z,2017,8,,,2017-08-09T15:00:28Z,,0,0,09000064828d1da6
FDA-2016-N-2527-8032,FDA,FDA-2016-N-2527,Exhibit F-1 - First Supplement to Citizen Petition re Comment from RAI Services Company,Supporting & Related Material,Background Material,2017-08-09T04:00:00Z,2017,8,,,2017-08-09T15:01:54Z,,0,0,09000064828d2eb4
FDA-2016-N-2527-8036,FDA,FDA-2016-N-2527,Exhibit G-3 - Attachment 2 to Second Supplement to Citizen Petition re Comment from RAI Services Company,Supporting & Related Material,Background Material,2017-08-09T04:00:00Z,2017,8,,,2017-08-09T14:59:32Z,,0,0,09000064828d1da8
FDA-2016-N-2527-8028,FDA,FDA-2016-N-2527,Exhibit D - Analysis of NNN Proposed Rule re Comment from RAI Services Company,Supporting & Related Material,Background Material,2017-08-09T04:00:00Z,2017,8,,,2017-08-09T13:59:26Z,,0,0,09000064828d2eb0
FDA-2016-N-2527-8035,FDA,FDA-2016-N-2527,Exhibit G-2 - Attachment 1 to Second Supplement to Citizen Petition re Comment from RAI Services Company,Supporting & Related Material,Background Material,2017-08-09T04:00:00Z,2017,8,,,2017-08-09T14:59:56Z,,0,0,09000064828d1da7
FDA-2016-N-2527-8021,FDA,FDA-2016-N-2527,Exhibit A - Reference List re Comment from RAI Services Company,Supporting & Related Material,Background Material,2017-08-07T04:00:00Z,2017,8,,,2017-08-07T19:01:38Z,,0,0,09000064828d2ead
FDA-2016-N-2527-2690,FDA,FDA-2016-N-2527,PRIA Reference 39 - Establishment Registration & Tobacco Product Listing Sample,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:52:12Z,,0,0,0900006482605576
FDA-2016-N-2527-2651,FDA,FDA-2016-N-2527,PRIA Reference List (3),Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:23:46Z,,0,0,090000648260527e
FDA-2016-N-2527-2663,FDA,FDA-2016-N-2527,PRIA Reference 12 - The Formation of Nitrosamines in Experimental Tobacco,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:50:26Z,,0,0,090000648260535f
FDA-2016-N-2527-2660,FDA,FDA-2016-N-2527,PRIA Reference 9 - Are We Finally Winning the War on Cancer,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:50:13Z,,0,0,090000648260550f
FDA-2016-N-2527-2653,FDA,FDA-2016-N-2527,"PRIA Reference 2 - Statistical Report - Tobacco Report Symbol, 2015",Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:49:44Z,,0,0,0900006482605508
FDA-2016-N-2527-2655,FDA,FDA-2016-N-2527,"PRIA Reference 4 - National Vital Statistical Reports, 2015",Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:49:51Z,,0,0,090000648260550a
FDA-2016-N-2527-2682,FDA,FDA-2016-N-2527,PRIA Reference 31 - U.S. Business Administration,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:51:43Z,,0,0,090000648260556e
FDA-2016-N-2527-2664,FDA,FDA-2016-N-2527,PRIA Reference 13 - Code Date Catalog,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:50:31Z,,0,0,0900006482605360
FDA-2016-N-2527-2676,FDA,FDA-2016-N-2527,PRIA Reference 25 - Topics for Biological and Biochemical Research,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:51:20Z,,0,0,0900006482605560
FDA-2016-N-2527-2688,FDA,FDA-2016-N-2527,PRIA Reference 37 - Occupation Employment Statistics,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:52:04Z,,0,0,0900006482605574
FDA-2016-N-2527-2652,FDA,FDA-2016-N-2527,PRIA Reference 1 - Combustible and Smokeless Tobacco Use,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:49:36Z,,0,0,0900006482605507
FDA-2016-N-2527-2656,FDA,FDA-2016-N-2527,"PRIA Reference 5 - Smoking and Tobacco Use, 2014",Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:49:54Z,,0,0,090000648260550b
FDA-2016-N-2527-2679,FDA,FDA-2016-N-2527,PRIA Reference 28 - Patients Perceived Health Status Following Primary,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:51:30Z,,0,0,0900006482605563
FDA-2016-N-2527-2685,FDA,FDA-2016-N-2527,PRIA Reference 34 - Carcinogenic Tobacco Specific N-Nitrosamines in U.S,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:51:53Z,,0,0,0900006482605571
FDA-2016-N-2527-2666,FDA,FDA-2016-N-2527,PRIA Reference 15 - Literature Study  N-Nitrosamines in Tobacco Products,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:50:40Z,,0,0,0900006482605362
FDA-2016-N-2527-2671,FDA,FDA-2016-N-2527,"PRIA Reference 20 - SEER Cancer Statistics Review, 1975-2012",Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:51:00Z,,0,0,0900006482605367
FDA-2016-N-2527-2658,FDA,FDA-2016-N-2527,"PRIA Reference 7 - Raising th Excise Tax on Cigarettes  Effects on Health and the Federal  Budget, 2012",Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:50:05Z,,0,0,090000648260550d
FDA-2016-N-2527-2680,FDA,FDA-2016-N-2527,PRIA Reference 29 - Reformulation Cost Model FINAL REPORT,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:51:35Z,,0,0,0900006482605564
FDA-2016-N-2527-2659,FDA,FDA-2016-N-2527,PRIA Reference 8 - The 2015 Long Term Budget Outlook,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:50:09Z,,0,0,090000648260550e
FDA-2016-N-2527-2661,FDA,FDA-2016-N-2527,PRIA Reference 10 - The Cost Effectiveness of Community Based Screening for Oral Cancer,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:50:18Z,,0,0,0900006482605510
FDA-2016-N-2527-2675,FDA,FDA-2016-N-2527,PRIA Reference 24 - Regional Convenience Store Markup Percentages,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:51:17Z,,0,0,090000648260555f
FDA-2016-N-2527-2683,FDA,FDA-2016-N-2527,PRIA Reference 32 - Statistics of US Businesses 2013,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:51:46Z,,0,0,090000648260556f
FDA-2016-N-2527-2691,FDA,FDA-2016-N-2527,PRIA Reference 40 - FDA's Electronic Reading Room - Warning Letters Sample,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:52:16Z,,0,0,0900006482605577
FDA-2016-N-2527-2662,FDA,FDA-2016-N-2527,PRIA Reference 11 - An Interim Determination of Health Gain from Oral Cancer,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:50:21Z,,0,0,090000648260535e
FDA-2016-N-2527-2669,FDA,FDA-2016-N-2527,PRIA Reference 18 - Is Addiction Rational  Theory and Evidence,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:50:53Z,,0,0,0900006482605365
FDA-2016-N-2527-2654,FDA,FDA-2016-N-2527,PRIA Reference 3 - Adjusting the Value of a Statistical Life,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:49:47Z,,0,0,0900006482605509
FDA-2016-N-2527-2684,FDA,FDA-2016-N-2527,PRIA Reference 33 - Tobacco-Specific Nitrosamines in New Tobacco Products,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:51:50Z,,0,0,0900006482605570
FDA-2016-N-2527-2668,FDA,FDA-2016-N-2527,"PRIA Reference 17 - Tobacco and the Economy  Farms, Jobs and",Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:50:49Z,,0,0,0900006482605364
FDA-2016-N-2527-2687,FDA,FDA-2016-N-2527,PRIA Reference 36 - CPI Report 2015 Dec,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:52:00Z,,0,0,0900006482605573
FDA-2016-N-2527-2692,FDA,FDA-2016-N-2527,PRIA Reference 41 - Informing the NNN Product Standard RIA Memo,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:52:19Z,,0,0,090000648260558b
FDA-2016-N-2527-2665,FDA,FDA-2016-N-2527,PRIA Reference 14 - Recurrence Rate and Shift in Histopathological Differentiation of,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:50:36Z,,0,0,0900006482605361
FDA-2016-N-2527-2667,FDA,FDA-2016-N-2527,PRIA Reference 16 - Prospective Investigation of the Cigarette Smoking,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:50:44Z,,0,0,0900006482605363
FDA-2016-N-2527-2670,FDA,FDA-2016-N-2527,PRIA Reference 19 - Report of Nationally Representative Values for the Non,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:50:56Z,,0,0,0900006482605366
FDA-2016-N-2527-2657,FDA,FDA-2016-N-2527,"PRIA Reference 6 - Smoking and Tobacco Use, 2015",Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:50:02Z,,0,0,090000648260550c
FDA-2016-N-2527-2686,FDA,FDA-2016-N-2527,PRIA Reference 35 - 50 Year Trends in Smoking Related Mortality in the U.S,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:51:57Z,,0,0,0900006482605572
FDA-2016-N-2527-2689,FDA,FDA-2016-N-2527,PRIA Reference 38 - Federal Trade Commission Smokeless Tobacco Product Report,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:52:08Z,,0,0,0900006482605575
FDA-2016-N-2527-2677,FDA,FDA-2016-N-2527,PRIA Reference 26 - The Determination of Tobacco Specific Nitrosamines in,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:51:24Z,,0,0,0900006482605561
FDA-2016-N-2527-2678,FDA,FDA-2016-N-2527,PRIA Reference 27 - Valuing Reductions in Fatal Illness Risks,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:51:27Z,,0,0,0900006482605562
FDA-2016-N-2527-2681,FDA,FDA-2016-N-2527,PRIA Reference 30 - FDA Labeling Cost Model FINAL,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:51:38Z,,0,0,0900006482605565
FDA-2016-N-2527-2693,FDA,FDA-2016-N-2527,PRIA Reference 42 - Crop Production 2014 Summary,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:52:23Z,,0,0,090000648260558c
FDA-2016-N-2527-2672,FDA,FDA-2016-N-2527,PRIA Reference 21 - The Incentives Created by a Harm Reduction Approach,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:51:03Z,,0,0,090000648260555c
FDA-2016-N-2527-2673,FDA,FDA-2016-N-2527,PRIA Reference 22 - Proposal for Basic Research on Tobacco Fermentation,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:51:07Z,,0,0,090000648260555d
FDA-2016-N-2527-2674,FDA,FDA-2016-N-2527,PRIA Reference 23 - The Value of Health and Longevity,Supporting & Related Material,Background Material,2017-05-23T04:00:00Z,2017,5,,,2017-05-23T16:51:13Z,,0,0,090000648260555e
FDA-2016-N-2527-0259,FDA,FDA-2016-N-2527,Letter from Robert Ellis to FDA,Other,Letter(s),2017-03-16T04:00:00Z,2017,3,2017-03-16T04:00:00Z,,2017-03-16T16:19:44Z,,0,0,09000064825011b0
FDA-2016-N-2527-0268,FDA,FDA-2016-N-2527,Request to Extend Comment Period from RAI Services Company,Other,Request for Extension,2017-03-16T04:00:00Z,2017,3,2017-03-16T04:00:00Z,,2017-03-16T16:34:58Z,,0,0,0900006482509dbd
FDA-2016-N-2527-0269,FDA,FDA-2016-N-2527,Request to Extend Comment Period from Reason Foundation,Other,Request for Extension,2017-03-16T04:00:00Z,2017,3,2017-03-16T04:00:00Z,,2017-03-16T16:35:11Z,,0,0,090000648250a4d0
FDA-2016-N-2527-0255,FDA,FDA-2016-N-2527,Letter from The Honorable Andy Barr to DHHS,Other,Letter(s),2017-03-16T04:00:00Z,2017,3,2017-03-16T04:00:00Z,,2017-03-16T16:18:58Z,,0,0,09000064824f3b35
FDA-2016-N-2527-0261,FDA,FDA-2016-N-2527,"Request to Extend Comment Period from Cheyenne International, LLC",Other,Request for Extension,2017-03-16T04:00:00Z,2017,3,2017-03-16T04:00:00Z,,2017-03-16T16:20:12Z,,0,0,0900006482504f00
FDA-2016-N-2527-0226,FDA,FDA-2016-N-2527,TAB B 2015-1102 Smokeless NNN Proposed Rule Track Changes re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-31T05:00:00Z,2017,1,,,2017-02-07T14:49:58Z,,0,0,09000064824a3365
FDA-2016-N-2527-0227,FDA,FDA-2016-N-2527,TAB C 2015-1102 Smokeless NNN PRIA as Cleared by OMB re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-31T05:00:00Z,2017,1,,,2017-02-07T14:50:06Z,,0,0,09000064824a3366
FDA-2016-N-2527-0223,FDA,FDA-2016-N-2527,TAB A 2015-1102 Smokeless NNN PRIA as Submitted to OMB re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-31T05:00:00Z,2017,1,,,2017-02-07T14:49:33Z,,0,0,09000064824a3362
FDA-2016-N-2527-0224,FDA,FDA-2016-N-2527,TAB A 2015-1102 Smokeless NNN Proposed Rule as Submitted to OMB  re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-31T05:00:00Z,2017,1,,,2017-02-07T14:49:43Z,,0,0,09000064824a3363
FDA-2016-N-2527-0222,FDA,FDA-2016-N-2527,Memorandum to FDA DDM Tobacco Smokeless NNN Proposed Rule  re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-31T05:00:00Z,2017,1,,,2017-02-07T14:49:25Z,,0,0,09000064824a3361
FDA-2016-N-2527-0225,FDA,FDA-2016-N-2527,TAB B 2015-1102 Smokeless NNN PRIA Track Changes re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-31T05:00:00Z,2017,1,,,2017-02-07T14:49:51Z,,0,0,09000064824a3364
FDA-2016-N-2527-0228,FDA,FDA-2016-N-2527,TAB C 2015-1102 Smokeless NNN Proposed Rule as Cleared by OMB re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-31T05:00:00Z,2017,1,,,2017-02-07T14:50:13Z,,0,0,09000064824a3367
FDA-2016-N-2527-0114,FDA,FDA-2016-N-2527,Reference 107 - Hecht-2016-Exposure and Metabolic Activation B re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:46:36Z,,0,0,090000648248ec25
FDA-2016-N-2527-0117,FDA,FDA-2016-N-2527,"Reference 110 - Stockwell, Impact of Smoking and Smokeless re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products",Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:46:50Z,,0,0,090000648248ec28
FDA-2016-N-2527-0121,FDA,FDA-2016-N-2527,Reference 114 - Lee-2009-Systematic Review of the Relation Bet re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:47:09Z,,0,0,090000648248ec33
FDA-2016-N-2527-0204,FDA,FDA-2016-N-2527,"Reference 198 - Mirvish, 1975, Formation of N-Nitroso Compounds re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products",Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:54:38Z,,0,0,090000648248ecd5
FDA-2016-N-2527-0055,FDA,FDA-2016-N-2527,"Reference 48 - Morin, et al, Evolution of Tobacco Specific Ni re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products",Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:41:52Z,,0,0,090000648248ee8b
FDA-2016-N-2527-0092,FDA,FDA-2016-N-2527,Reference 85 - Digard-2013-Multi-Analyte Approach for Determi re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:44:54Z,,0,0,090000648248eee3
FDA-2016-N-2527-0129,FDA,FDA-2016-N-2527,Reference 122 - Zhou-2013-Smokeless Tobacco and Risk of Head a re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:47:46Z,,0,0,090000648248f04c
FDA-2016-N-2527-0133,FDA,FDA-2016-N-2527,Reference 126 - Yanovitzky-2000-Effect of Media Coverage and P re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:48:03Z,,0,0,090000648248f052
FDA-2016-N-2527-0134,FDA,FDA-2016-N-2527,Reference 127 - Cram-2003-The Impact of a Celebrity Promotiona re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:48:08Z,,0,0,090000648248f053
FDA-2016-N-2527-0197,FDA,FDA-2016-N-2527,"Reference 191 - Boffetta, 2005, Smokeless Tobacco Use and Risk of Pancreatic Cancer re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products",Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:54:01Z,,0,0,090000648248f0da
FDA-2016-N-2527-0026,FDA,FDA-2016-N-2527,Reference 19 - Foulds-2008-Is Low-Nicotine Marlboro Snus Real re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:39:29Z,,0,0,090000648248ede3
FDA-2016-N-2527-0037,FDA,FDA-2016-N-2527,Reference 30 - Brunnemann-1996-Formation and Analysis of Toba re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:40:24Z,,0,0,090000648248ee03
FDA-2016-N-2527-0043,FDA,FDA-2016-N-2527,Reference 36 - Burton-1994-Relationship Between Tobacco-Speci re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:40:51Z,,0,0,090000648248ee12
FDA-2016-N-2527-0013,FDA,FDA-2016-N-2527,Reference 6 - Song-2016-Chemical and Toxicological Character re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:38:26Z,,0,0,090000648248edc9
FDA-2016-N-2527-0067,FDA,FDA-2016-N-2527,Reference 60 - Hatsukami-1988-Topographical Features of Smoke re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:42:53Z,,0,0,090000648248eebf
FDA-2016-N-2527-0098,FDA,FDA-2016-N-2527,"Reference 91 - Brown, Patent US20050043515A1 re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products",Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:45:22Z,,0,0,090000648248eeeb
FDA-2016-N-2527-0106,FDA,FDA-2016-N-2527,"Reference 99 - Stepanov, 2005, Tobacco Specific Nitrosamines and re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products",Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:45:58Z,,0,0,090000648248efd3
FDA-2016-N-2527-0131,FDA,FDA-2016-N-2527,"Reference 124 - Chakravorty, B,  Cessation Related Perceptions re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products",Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:47:54Z,,0,0,090000648248f04e
FDA-2016-N-2527-0145,FDA,FDA-2016-N-2527,Reference 138 - Song-2009-Perceptions of Smoking-related Risks re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:49:17Z,,0,0,090000648248f078
FDA-2016-N-2527-0153,FDA,FDA-2016-N-2527,"Reference 147 - Hoffmann, 1990,  Advances in Tobacco Carcinogenesis Chapt 3 re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products",Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:49:58Z,,0,0,090000648248ec78
FDA-2016-N-2527-0156,FDA,FDA-2016-N-2527,"Reference 150 - Prokopczyk, 1991, A Study of Betel Quid Carcinogenesis re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products",Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:50:13Z,,0,0,090000648248ec7d
FDA-2016-N-2527-0183,FDA,FDA-2016-N-2527,Reference 177 - McIntee-2000-Metabolism of N'-nitrosonornicoti re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:52:53Z,,0,0,090000648248ecad
FDA-2016-N-2527-0196,FDA,FDA-2016-N-2527,Reference 190 - Definition of cancer slope factor re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:53:56Z,,0,0,090000648248f0d7
FDA-2016-N-2527-0212,FDA,FDA-2016-N-2527,"Reference 206 - Stepanov, et al, Tobacco specific Nitrosamines in Smokeless re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products",Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:55:26Z,,0,0,090000648248f0f8
FDA-2016-N-2527-0008,FDA,FDA-2016-N-2527,"Reference 1 - IARC, Monographs on the Evaluation of Carcinogenic Risks re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products",Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:37:58Z,,0,0,090000648248ed71
FDA-2016-N-2527-0078,FDA,FDA-2016-N-2527,Reference 71 - Jitnarin-2015-Tobacco Use Pattern among a Nati re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products,Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:43:46Z,,0,0,090000648248ea81
FDA-2016-N-2527-0079,FDA,FDA-2016-N-2527,"Reference 72 - Hecht, 2008, Exposure to Nicotine and Tobacco-specific re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products",Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:43:51Z,,0,0,090000648248ea82
FDA-2016-N-2527-0111,FDA,FDA-2016-N-2527,"Reference 104 - Idris, 1995, Toombak Dipping and Cancer of the Oral Cavity re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products",Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:46:20Z,,0,0,090000648248ebd5
FDA-2016-N-2527-0053,FDA,FDA-2016-N-2527,"Reference 46 - Staaf, Formation of Tobacco-specific Nitrosami re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products",Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:41:42Z,,0,0,090000648248ee89
FDA-2016-N-2527-0064,FDA,FDA-2016-N-2527,"Reference 57 - EPA, Risk Assessment Guidance re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products",Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:42:39Z,,0,0,090000648248eeab
FDA-2016-N-2527-0105,FDA,FDA-2016-N-2527,"Reference 98 - Hecht, 2007, Similar Exposure to a Tobacco-sp re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products",Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:45:54Z,,0,0,090000648248efd2
FDA-2016-N-2527-0130,FDA,FDA-2016-N-2527,"Reference 123 - Agaku, 2012, Evaluation of Factors Influencing re Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products",Supporting & Related Material,Background Material,2017-01-26T05:00:00Z,2017,1,,,2017-01-26T22:47:50Z,,0,0,090000648248f04d